Currency in EUR
Last close As at 02/06/2023
EUR28.82
▲ −0.66 (−2.24%)
Market capitalisation
EUR4,118m
Research: Industrials
Mytilineos reported solid Q1 results with EBITDA growing 20% y-o-y sustained by strong performances in the Power & Gas business and EPC & Infrastructure activities. We see Mytilineos as well positioned to reach our full year forecasts, on which basis the stock is trading on less than 7x FY19 P/E, less than 5x EV/EBITDA and offers an annual free cash flow yield of over 14% in the period FY19–22e.
Written by
Dario Carradori
Mytilineos |
Power growth |
Q1 results update |
General industrials |
3 May 2019 |
Share price performance
Business description
Next events
Analyst
Mytilineos is a research client of Edison Investment Research Limited |
Mytilineos reported solid Q1 results with EBITDA growing 20% y-o-y sustained by strong performances in the Power & Gas business and EPC & Infrastructure activities. We see Mytilineos as well positioned to reach our full year forecasts, on which basis the stock is trading on less than 7x FY19 P/E, less than 5x EV/EBITDA and offers an annual free cash flow yield of over 14% in the period FY19–22e.
Year end |
EBITDA |
Net income* |
EPS* |
DPS |
P/E |
Yield |
12/17 |
299 |
143 |
1.02 |
0.32 |
9.5 |
3.3 |
12/18 |
290 |
144 |
1.01 |
0.36 |
9.6 |
3.7 |
12/19e |
359 |
206 |
1.43 |
0.50 |
6.7 |
5.2 |
12/20e |
344 |
197 |
1.37 |
0.48 |
7.0 |
5.0 |
Note: *Net income and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
Q1 results on track to reach our full year forecasts
Mytilineos reported Q1 results with EBITDA up 20% y-o-y to €92m, a strong growth rate that is consistent with the trend we expect for the full year (+24% yoy). EBITDA growth drove 21% y-o-y EPS growth to €0.348. The company does not provide divisional data, but we believe that the key contributors to growth were the Power & Gas business (higher margins thanks to higher power prices and gas imports at a discount to market prices; higher volumes, up 23% y-o-y for gas plants and 84% yoy for renewables; and higher supply market share) and the EPC & Infrastructure activity (new contracts in Ghana and Kazakhstan). The Metallurgy business achieved similar profitability to Q118 despite a decline in market prices for aluminium, thanks to cost control and hedging in place.
Growth projects could add to organic growth
Following Q1 results, we view Mytilineos as on track to reach our forecasts for FY19. The growth we forecast for this year is mostly organic, but as explained in our recent initiation Cash flow miner, growth generator, we estimate c €800m balance sheet headroom by 2022 to deploy for new investments. Mytilineos is evaluating the construction of a new alumina refinery plant and of a new gas-fired power plant. We estimate the projects would have a combined 20% project IRR, well above the cost of capital, and would boost current EBITDA by c 50%. The final investment decision on the power plant project has been taken and construction could start before the end of 2019, provided a construction licence is granted.
Valuation: 14%+ FCF yield, large discount to peers
Based on our unchanged estimates we forecast 14–16% free cash flow (FCF) yield (pre-growth capex) over 2019–22e. By applying the median valuation metrics of European diversified industrials, we calculate an average value of c €16.5/share for Mytilineos, a 70%+ premium to the current share price. Similarly, a SOTP valuation using the EV/EBITDA of comparable peers implies more than a 40% discount to fair value. Finally, our DCF-based SOTP is €12.3/share, implying c 30% upside, even assuming a 15% discount to reflect the diversified business model.
Exhibit 1: Financial summary
Accounts: IFRS; year end: 31 December; €m |
2016 |
2017 |
2018 |
2019e |
2020e |
2021e |
2022e |
Income statement |
|
|
|
|
|
|
|
Total revenues |
1,246 |
1,527 |
1,527 |
2,234 |
2,356 |
2,656 |
3,026 |
Cost of sales |
(972) |
(1,143) |
(1,150) |
(1,771) |
(1,903) |
(2,176) |
(2,524) |
Gross profit |
274 |
384 |
376 |
463 |
453 |
481 |
502 |
SG&A (expenses) |
(76) |
(86) |
(88) |
(98) |
(103) |
(107) |
(110) |
R&D costs |
(0) |
(0) |
(0) |
(0) |
(0) |
(0) |
(0) |
Other income/(expense) |
24 |
1 |
2 |
(6) |
(6) |
(6) |
(6) |
Exceptionals and adjustments |
0 |
6 |
(6) |
0 |
0 |
0 |
0 |
Depreciation and amortisation |
(73) |
(73) |
(79) |
(83) |
(87) |
(89) |
(89) |
Reported EBIT |
148 |
232 |
205 |
276 |
257 |
278 |
296 |
Finance income/(expense) |
(57) |
(43) |
(38) |
(14) |
(9) |
(4) |
3 |
Other income/(expense) |
(6) |
(7) |
1 |
1 |
1 |
1 |
1 |
Exceptionals and adjustments |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Reported PBT |
85 |
182 |
168 |
263 |
248 |
275 |
299 |
Income tax expense (includes exceptionals) |
(21) |
(24) |
(24) |
(58) |
(52) |
(55) |
(60) |
Reported net income |
61 |
158 |
140 |
205 |
196 |
220 |
240 |
Basic average number of shares, m |
117 |
142.9 |
142.9 |
142.9 |
142.9 |
142.9 |
142.9 |
Basic EPS |
0.3 |
1.08 |
0.99 |
1.43 |
1.37 |
1.53 |
1.67 |
Adjusted EBITDA |
222 |
299 |
290 |
359 |
344 |
367 |
385 |
Adjusted EBIT |
148 |
226 |
211 |
276 |
257 |
278 |
296 |
Adjusted PBT |
85 |
175 |
174 |
263 |
248 |
275 |
299 |
Adjusted net income |
64 |
143 |
144 |
206 |
197 |
221 |
241 |
Adjusted EPS (€) |
0.29 |
1.02 |
1.01 |
1.43 |
1.37 |
1.53 |
1.67 |
Adjusted diluted EPS (€) |
0.29 |
1.02 |
1.01 |
1.43 |
1.37 |
1.53 |
1.67 |
DPS (€) |
0.00 |
0.32 |
0.36 |
0.50 |
0.48 |
0.54 |
0.58 |
Adjusted EBIT margin |
12% |
15% |
13% |
12% |
11% |
10% |
10% |
Balance sheet |
|
|
|
|
|
|
|
Property, plant and equipment |
1,073 |
1,137 |
1,142 |
1,165 |
1,159 |
1,151 |
1,143 |
Goodwill |
209 |
209 |
209 |
209 |
209 |
209 |
209 |
Intangible assets |
243 |
236 |
235 |
235 |
235 |
235 |
235 |
Other non-current assets |
326 |
282 |
272 |
272 |
272 |
271 |
271 |
Total non-current assets |
1,851 |
1,864 |
1,858 |
1,882 |
1,875 |
1,867 |
1,859 |
Cash and equivalents |
198 |
161 |
208 |
192 |
198 |
219 |
240 |
Inventories |
257 |
159 |
184 |
184 |
184 |
184 |
184 |
Trade and other receivables |
800 |
1,018 |
1,059 |
1,138 |
1,226 |
1,323 |
1,440 |
Other current assets |
1 |
16 |
32 |
32 |
32 |
32 |
32 |
Total current assets |
1,257 |
1,354 |
1,483 |
1,547 |
1,641 |
1,758 |
1,896 |
Non-current loans and borrowings |
429 |
599 |
534 |
434 |
334 |
234 |
134 |
Other non-current liabilities |
360 |
298 |
375 |
368 |
360 |
353 |
346 |
Total non-current liabilities |
789 |
897 |
909 |
802 |
694 |
587 |
480 |
Trade and other payables |
571 |
575 |
608 |
669 |
736 |
810 |
891 |
Current loans and borrowings |
388 |
130 |
64 |
64 |
64 |
64 |
64 |
Other current liabilities |
76 |
184 |
198 |
198 |
198 |
198 |
198 |
Total current liabilities |
1,035 |
890 |
871 |
932 |
999 |
1,072 |
1,153 |
Equity attributable to company |
989 |
1,377 |
1,508 |
1,641 |
1,768 |
1,910 |
2,065 |
Non-controlling interest |
295 |
54 |
53 |
54 |
55 |
56 |
57 |
Cash flow statement |
|
|
|
|
|
|
|
Profit for the year |
64 |
158 |
144 |
205 |
196 |
220 |
240 |
Taxation expenses |
21 |
24 |
23 |
58 |
52 |
55 |
60 |
Net finance expenses |
48 |
42 |
38 |
13 |
9 |
3 |
(3) |
Depreciation and amortisation |
76 |
76 |
81 |
83 |
87 |
89 |
89 |
Other adjustments |
(9) |
(9) |
(7) |
(25) |
(25) |
(25) |
(25) |
Movements in working capital |
(90) |
(38) |
(68) |
(19) |
(21) |
(23) |
(36) |
Interest paid / received |
(48) |
(32) |
(31) |
(13) |
(9) |
(3) |
3 |
Income taxes paid |
(14) |
(6) |
(18) |
(58) |
(52) |
(55) |
(60) |
Cash from operations (CFO) |
48 |
214 |
162 |
244 |
237 |
261 |
267 |
Capex |
(103) |
(127) |
(85) |
(106) |
(81) |
(81) |
(81) |
Acquisitions & disposals net |
1 |
1 |
20 |
0 |
0 |
0 |
0 |
Other investing activities |
5 |
9 |
18 |
18 |
18 |
18 |
18 |
Cash used in investing activities (CFIA) |
(97) |
(117) |
(47) |
(88) |
(63) |
(63) |
(63) |
Net proceeds from issue of shares |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Movements in debt |
87 |
(81) |
(128) |
(100) |
(100) |
(100) |
(100) |
Dividends paid |
(3) |
(5) |
(46) |
(71) |
(68) |
(77) |
(83) |
Other financing activities |
(41) |
(48) |
106 |
0 |
0 |
0 |
0 |
Cash from financing activities (CFF) |
43 |
(134) |
(68) |
(171) |
(168) |
(177) |
(183) |
Increase/(decrease) in cash and equivalents |
(6) |
(37) |
47 |
(16) |
6 |
21 |
21 |
Cash and equivalents at end of period |
198 |
161 |
208 |
192 |
198 |
219 |
240 |
Net (debt) cash |
(618) |
(568) |
(390) |
(306) |
(200) |
(79) |
42 |
Movement in net (debt) cash over period |
(618) |
50 |
178 |
84 |
106 |
121 |
121 |
Source: Mytilineos data, Edison Investment Research.
|
|
During 2019, Immunovia will focus on optimising the IMMray PanCan-d test in preparation for the start of a commercial private testing service for pancreatic cancer (PDAC). The sample optimisation study should end in Q2. In H219, accreditation of the Swedish and US laboratories is required to enable a private PDAC test service by Q120. The 2,000 patient PanFAM-1 prospective clinical trial is still recruiting patients and might report primary data on early-stage PDAC detection in December 2019. Earlier-stage opportunities are: Type II diabetes, early symptoms of PDAC, lung cancer and rheumatoid arthritis. Our valuation remains at SEK3.5bn.
Get access to the very latest content matched to your personal investment style.